Collegium Targets $65M-$75M Azstarys Revenue, Holds Jornay PM at $190M-$200M
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
collegium-pharmaceuticalazstarys
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Collegium Pharmaceutical announced revenue projections for its key products on 6 August 2026. The company targets $65 million to $75 million in 2026 sales for its ADHD treatment Azstarys. It concurrently reaffirmed its forecast for Jornay PM, another ADHD medication, at $190 million to $200 million for the same period. These figures represent the company's public guidance for its product portfolio's financial performance.
Revenue guidance provides critical insight into a pharmaceutical company's commercial execution and product uptake. For Collegium, these projections for Azstarys and Jornay PM come amid a competitive market for attention-deficit/hyperactivity disorder treatments. The company has been strategically commercializing these assets following their respective launches. The reaffirmation of Jornay PM's substantial target suggests stable performance, while the Azstarys range indicates its growth trajectory within the portfolio.
The broader pharmaceutical sector faces ongoing pricing pressures and regulatory scrutiny. Companies are evaluated on their ability to meet or exceed stated financial targets. Collegium's guidance places Azstarys as a smaller but growing contributor compared to the more established Jornay PM. This differentiation is crucial for investors assessing the product mix and future revenue diversification.
Product-specific revenue forecasts allow markets to model a company's total revenue potential. They serve as a benchmark against which actual quarterly earnings are measured. Missed or exceeded guidance often results in significant stock price movements, making these announcements material events for shareholders.
Collegium's stock, traded under the ticker COLL, closed at $147.40, down 0.48% on the day of the announcement. The stock traded within a daily range of $146.31 to $149.44. This price movement occurred as the market processed the new revenue guidance.
The $65M-$75M Azstarys target establishes a baseline for its 2026 performance. This range represents a specific financial expectation for the product's first full year of significant commercialization. The $190M-$200M projection for Jornay PM indicates it remains the larger revenue driver, comprising a majority of the company's product sales.
A comparison of the two targets shows Jornay PM's revenue is projected to be approximately 2.7 to 3.1 times greater than Azstarys's revenue. This disparity highlights the differing stages of commercial maturity between the two products. The combined mid-point of both targets suggests over $270 million in product revenue for 2026.
The revenue guidance suggests Collegium is executing a dual-product strategy within the ADHD market. Jornay PM's reaffirmed target indicates management confidence in its sustained performance. The Azstarys projection provides a measurable goal for its market penetration efforts. Investors will monitor prescription data closely to gauge progress toward these figures.
A potential risk exists if prescription growth for either product fails to meet internal expectations, which could result in guidance revisions. The competitive landscape includes established treatments from companies like Takeda Pharmaceutical and Novartis AG. Market share gains are necessary to achieve the stated revenue ranges.
Institutional investors are likely positioned long based on the company's specialty pharma focus and commercial strategy. Analyst models will incorporate these figures into earnings per share estimates. The stock's performance will be tied to quarterly updates demonstrating progress toward these annual targets.
The next significant catalyst will be Collegium's Q3 2026 earnings report, typically released in early November. This report will provide the first concrete data point on progress toward the full-year guidance. Investors should monitor prescription trends through第三方 data providers like IQVIA throughout the quarter.
Key levels to watch for COLL stock include technical support near $145 and resistance around the $150 level. A sustained break above $150 could indicate renewed bullish momentum following the guidance announcement. Conversely, a break below $145 might signal investor skepticism regarding the targets.
The company's next major investor presentation, likely at a healthcare conference in September, may provide additional color on the commercial strategies for both products. Management commentary during these events often offers insights into underlying demand trends and competitive dynamics.
Azstarys is a prescription medication approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients aged six years and older. It is a central nervous system stimulant that combines serdexmethylphenidate and dexmethylphenidate. The product was designed to provide extended duration of effect for symptom control throughout the day.
Jornay PM is an innovative methylphenidate formulation designed with a delayed-release and extended-release profile. It is administered in the evening, with symptoms controlled upon waking the next morning. This dosing schedule aims to eliminate the morning rush to medicate before school or work, differentiating it from immediate-release and traditional extended-release stimulants.
While exact percentages vary by quarter, Jornay PM and Azstarys collectively represent the majority of Collegium's product revenue. Based on the 2026 guidance midpoints, these two products would generate approximately $275 million in combined revenue. The company may have additional revenue streams from legacy products or partnerships, but these two assets form the core of its growth strategy.
Collegium Pharmaceutical's revenue guidance establishes clear benchmarks for evaluating its two primary ADHD products in 2026.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.